Correction to: CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic syndrome

Hongxia Liu¹ · Qinxia Xu² · Wenyan Huang³ · Qi Zhao⁴ · Zhihu Jiang¹ · Xinyu Kuang³ · Zhiling Li¹ · Huajun Sun¹ · Xiaoyan Qiu⁵

Published online: 30 January 2021

© Springer-Verlag GmbH Germany, part of Springer Nature 2021

Correction to: European Journal of Clinical Pharmacology

<https://doi.org/10.1007/s00228-019-02726-w>

The original publication of this paper contains two errors. We apologize for any inconvenience this may have caused.

1. The Median (Q25–Q75) of dose-adjusted C_0 of tacrolimus for the two genotypes of CYP3A4*1G, CYP3A4 rs4646437 and CYP3A7 rs10211 in Table 2 should be exchanged. The corrected table 2 is as followed:

The online version of the original article can be found at <https://doi.org/10.1007/s00228-019-02726-w>

✉ Huajun Sun
shj2049@126.com

✉ Xiaoyan Qiu
xyqiu@163.com

¹ Department of Pharmacy, Shanghai Children's Hospital, Shanghai Jiao Tong University, 355 Luding Road, Shanghai 200062, China

² Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China

³ Department of Nephrology and Rheumatology, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai 200062, China

⁴ College of Pharmacy, Fudan University, Shanghai, China

⁵ Department of Pharmacy, Huashan Hospital, Fudan University, 12 Middle Urumqi Road, Shanghai 200040, China

SNP	Number	Genotype	Median (Q25–Q75)	p
CYP3A5*3	39	A	54.2(42.3 – 80.0)	0.00006*
31	NA	90.7(65.7 – 171.5)		
CYP3A4*1G	30	T	59.6(42.8 – 83.1)	0.011
38	NT	82.6(58.5 – 169.7)		
CYP3A4 rs4646437	11	T	51.7 (32.1 – 91.0)	0.011
56	NT	73.6(54.5 – 133.7)		
CYP3A7 rs2257401	39	C	62.4(42.6 – 84.9)	0.001*
26	NC	90.7(62.7 – 192.6)		
CYP3A7 rs10211	34	G	59.6(42.4 – 80.2)	0.0004*
31	NG	101.8(64.2 – 187.3)		

2. The data “94%” in “the tacrolimus concentration in patients without CYP3A5*3 A allele was 94% higher than those with A allele (90.7 vs 54.2, P = 0.00006).” of the abstract should be “67%”.